Previous Close | 10.52 |
Open | 10.52 |
Bid | 10.59 x 800 |
Ask | 10.70 x 1000 |
Day's Range | 10.41 - 10.69 |
52 Week Range | 7.13 - 15.24 |
Volume | |
Avg. Volume | 2,367,160 |
Market Cap | 802.751M |
Beta (5Y Monthly) | 0.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.46 |
Earnings Date | Feb 07, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 35.33 |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.